Darunavir Ethanolate is also known by it’s brand name Prezista, and is used to treat HIV infection. In the class of protease inhibitors, darunavir ethanolate was approved by the FDA in June of 2006. What makes darunavir ethanolate unique is it’s ability to combat drug resistant strains of HIV in affected patients, as well as[…]
Darunavir Ethanolate continues to Prove it's Viability for HIV Treatment
Anti-Retroviral / Anti-HIV, Antiviral, Drug Research & Development API Tags: antiretroviralDarunavir EthanolateHIV infectionRitonavir Apr 23, 2012
Monotherapy with Darunavir is Where the "MONET" is
Anti-Retroviral / Anti-HIV, Drug Research & Development API Tags: AIDSDarunavir EthanolateHIVHIV virusRitonavir Sep 02, 2011
AIDS is a global pandemic whose cure has eluded scientists and doctors for more than 2 decades. Acquired immunodeficiency syndrome (AIDS) is caused by the Human Immunodeficiency Virus (HIV) which progressively undermines the strength of the immune system until such a time that the body becomes incapable of fighting off infections and vulnerable to opportunistic[…]
Darunavir Ethanolate – Anti-Retroviral / Anti-HIV Therapeutic
Anti-Retroviral / Anti-HIV, Drug Research & Development API Tags: Darunavir EthanolateHIVNorvir Jul 21, 2010
Darunavir Ethanolate CAS# 635728-49-3 is a second-generation protease inhibitor (PIs), designed specifically to overcome problems with the older agents in this class, such as indinavir. Darunavir was designed to form robust interactions with the protease enzyme from many strains of HIV, including strains from treatment-experienced patients with multiple resistance mutations to PIs. Darunavir is always[…]
